Korro Bio Stock (NASDAQ:KRRO)

Forecast Revenue Ownership Financials Chart

Previous Close

$13.47

52W Range

$5.20 - $55.89

50D Avg

$11.98

200D Avg

$18.68

Market Cap

$135.27M

Avg Vol (3M)

$246.50K

Beta

2.43

Div Yield

-

KRRO Company Profile

Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

112

IPO Date

Oct 03, 2019

Website

KRRO Performance

KRRO Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	$6.39M	$2.27M	-
Operating Income	$-121.86M	$-91.91M	$-84.53M
Net Income	$-117.26M	$-83.58M	$-81.17M
EBITDA	$-121.86M	$-88.34M	$-80.90M
Basic EPS	$-12.48	$-9.37	$-53.09
Diluted EPS	$-12.48	$-9.37	$-53.08

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
LBRX	LB Pharmaceuticals Inc Common Stock
SLN	Silence Therapeutics plc
ALT	Altimmune, Inc.
ANNX	Annexon, Inc.
ANRO	Alto Neuroscience, Inc.
ENGN	enGene Holdings Inc.
LRMR	Larimar Therapeutics, Inc.
DBVT	DBV Technologies S.A.
AMRN	Amarin Corporation plc
AURA	Aura Biosciences, Inc.